Results 41 to 50 of about 56,538 (251)

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. [PDF]

, 2010
A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action. Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis.
BRESCIA MORRA, VINCENZO, BRUNETTI, ARTURO, CAROTENUTO, BARBARA, LANZILLO, ROBERTA, Lus G, OREFICE, GIUSEPPE, Prinster A, Quarantelli M, RINALDI, CARLO, SALVATORE, ELENA, Spitaleri D, Tedeschi G, Vacca G, Ventrella G   +13 more
core   +1 more source

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis

Neurology, 2003
To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration.The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age ...
A. CIFELLI, M. WYLEZINSKA, P. JEZZARD, J. PALACE, ALECCI, MARCELLO, P. MATTHEWS   +5 more
openaire   +5 more sources

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source

High intensity interval training for people with Multiple Sclerosis: a systematic review [PDF]

, 2018
Background: Aerobic High Intensity Interval Training (HIIT) is safe in the general population and more efficient in improving fitness than continuous moderate intensity training.
Campbell, Evan, Coulter, Elaine H., Paul, Lorna   +2 more
core   +2 more sources

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

Therapeutic Advances in Neurological Disorders, 2011
Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing–remitting multiple sclerosis. Phase III studies have demonstrated comparable efficacy on clinical measures of disease activity, variable ...
Volker Limmroth, Norman Putzki, Norman J. Kachuck   +2 more
doaj   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009? [PDF]

, 2019
Background:Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Iezzoni, Lisa I, Kinkel, R Philip, Levin, Jonathan S, Machado, Helene T, Minden, Sarah L, Rosenthal, Meredith B   +5 more
core  

Network Localization of Fatigue in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo, Jaakko Kungshamn, Albert Bellmunt‐Gil, Silvia Tommasin, Abhineet Ojha, Matias Viitala, Juho Aaltonen, Jyrki Lötjönen, Juha Koikkalainen, Pauli Ylikotila, Patrizia Pantano, Merja Soilu‐Hänninen, Juho Joutsa   +12 more
wiley   +1 more source

Neural correlates of alerting and orienting impairment in multiple sclerosis patients. [PDF]

PLoS ONE, 2014
BackgroundA considerable percentage of multiple sclerosis patients have attentional impairment, but understanding its neurophysiological basis remains a challenge. The Attention Network Test allows 3 attentional networks to be studied.
Manuel Vázquez-Marrufo, Alejandro Galvao-Carmona, Javier J González-Rosa, Antonio R Hidalgo-Muñoz, Mónica Borges, Juan Luis Ruiz-Peña, Guillermo Izquierdo   +6 more
doaj   +1 more source

Interferons in relapsing remitting multiple sclerosis

The Lancet, 2003
Mark Freedman, John King, Joel Oger, Mohammad Sharief, Hans-Peter Hartung   +4 more
  +9 more sources

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source